Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5532-5537

  Grove, Jane I ^a,b   Lovering, Andrew L ^a   Guise, Christopher ^a   Race, Paul R ^a   Wrighton, Christopher J ^b   White, Scott A ^a   Hyde, Eva I ^a   Searle, Peter F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; NITROREDUCTASE; PRODRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GENETICS; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; EMBRYO; ENZYME ACTIVATION; ESCHERICHIA COLI; GENE THERAPY; HUMAN; HUMAN CELL; MUTANT; OVARY CARCINOMA; PRIORITY JOURNAL; SENSITIZATION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; AZIRIDINES; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; HUMANS; MUTAGENESIS, SITE-DIRECTED; NITROREDUCTASES; OVARIAN NEOPLASMS; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0141592778     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
2. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes - paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
3. Grove, J. I., Searle, P. F., Weedon, S. J., Green, N. K., McNeish, I. A., and Kerr, D. J. Virus directed enzyme prodrug therapy using CB1954. Anticancer Drug Design, 14: 461-472, 1999.
4. Knox, R. J., Friedlos, F., and Boland, M. The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev., 12: 195-212, 1993.
5. Knox, R. J., Friedlos, F., Jarman, M., and Roberts, J. J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol., 37: 4661-4669, 1988.
6. Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., and Collins, M. K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB 1954. Eur. J. Cancer, 31A: 2362-2370, 1995.
7. Weedon, S. J., Green, N. K., McNeish, I. A., Gilligan, M. G., Mautner, V., Wrighton, C. J., Mountain, A., Young, L. S., Kerr, D. J., and Searle, P. F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitrooductase. Int. J. Cancer, 86: 848-854, 2000.
8. Green, N. K., Youngs, D. J., Neoptolemos, J. P., Friedlos, F., Knox, R. J., Springer, C. J., Anlezark, G. M., Michael, N. P., Melton, R. G., Ford, M. J., Young, L. S., Kerr, D. J., and Searle, P. F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitmbenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther., 4: 229-238, 1997.
9. Bridgewater, J. A., Knox, R. J., Pitts, J. D., Collins, M. K., and Springer, C. J. The bystander effect of the nitroreductase CB1954 enzyme prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther., 8: 709-717, 1997.
10. McNeish, I. A., Green, N. K., Gilligan, M. G., Ford, M. J., Mautner, V., Young, L. S., Kerr, D. J., and Searle, P. F. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther., 5: 1061-1069, 1998.
11. Djeha, A. H., Hulme, A., Dexter, M. T., Mountain, A., Young, L. S., Searlc, P. F., Kerr, D. J., and Wrighton, C. J. Expression of E. coli B nitroreductase in established human tumour xenografts in mice results in potent anti-tumour and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther., 7: 721-731, 2000.
12. Djeha, A. H., Thomson, T. A., Leung, H., Searle, P. F., Young, L. S., Kerr, D. J., Harris, P. A., Mountain, A., and Wrighton, C. J. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol. Ther., 3: 233-240, 2001.
13. Chung-Faye, G., Palmer, D., Anderson, D., Clark, J., Downes, M., Baddeley, J., Hussain, S., Murray, P. I., Searle, P., Seymour, L., Harris, P. A., Ferry, D., and Kerr, D. J. Virus-directed, enzyme prodrug therapy with nitroimidazole rcductase: a Phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res., 7: 2662-2668, 2001.
14. Searle, P. F., Spiers, I., Simpson, J., and James, N. D. Cancer gene therapy: from science to clinical trials. Drug Deliv. Systems Sci., 2: 5-13, 2002.
15. Black, M. E., Newcomb, T. G., Wilson, H. M. P., and Loeb, L. A. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA, 93: 3525-3529, 1996.
16. Black, M. E., Kokoris, M. S., and Sabo, P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res., 61: 3022-3026, 2001.
17. Kokoris, M. S., Sabo, P., Adman, E. T., and Black, M. E. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther., 6: 1415-1426, 1999.
18. Parkinson, G. N., Skelly, J. V., and Neidle, S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J. Med. Chem., 43: 3624-3631, 2000.
19. Lovering, A. L., Hyde, E. I., Searle, P. F., and White, S. A. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7Å, 1.8Å and 2.4Å resolution. J. Mol. Biol., 309: 203-213, 2001.
20. Murray, N. E. Phage λ and molecular cloning. In: Hendrix R. (ed.), Lambda 11, pp. 395-431. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1983.
21. Elish, M. E., Pierce, J. R., and Earhart, C. F. Biochemical analysis of spontaneous fepA mutants of Escherichia coli. J. Gen. Microbiol., 134 (Pt 5): 1355-1364, 1988.
22. Miller, A. D., and Rosman, G. J. Improved retroviral vectors for gene transfer and expression. BioTechniques, 7: 980-988, 1989.
23. Adam, M. A., Ramesh, N., Miller, A. D., and Osborne, W. R. A. Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions. J. Virol., 65: 4985-4990, 1991.
24. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-72, 1977.
25. Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A., van Ormondt, H., Hoeben, R. C., and van der Eb, A. J. Characterization of 911: a new helper cell line for the titration and propagation of early-region-1-deleted adenoviral vectors. Hum. Gene Ther., 7: 215-222, 1996.
26. Alley, M. C., Scudiero, D. A., Marks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, D. L., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
27. Anlezark, G. M., Melton, R. G., Sherwood, R. F., Coles, B., Friedlos, F., and Knox, R. J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol., 44: 2289-2295, 1992.
28. Zenno, S., Kobori, T., Tanokura, M., and Saigo, K. Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J. Bacteriol., 180: 422-425, 1998.
29. Pantuck, A. J., Matherly, J., Zisman, A., Nguyen, D., Berger, F., Gambhir, S. S., Black, M. E., Belldegrun, A., and Wu, L. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum. Gene Ther., 13: 777-789, 2002.
30. Anlezark, G. M., Melton, R. G., Sherwood, R. F., Wilson, W. R., Denny, W. A., Palmer, B. D., Knox, R. J., Friedlos, F., and Williams, A. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol., 50: 609-618, 1995.
31. Friedlos, F., Denny, W. A., Palmer, B. D., and Springer, C. J. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem., 40: 1270-1275, 1997.
32. Wilson, W. R., Pullen, S. M., Hogg, A., Helsby, N. A., Hicks, K. O., and Denny, W. A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res., 62: 1425-1432, 2002.